AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1059
- Registration Number
- NCT00287534
- Locations
- 🇩🇪
Research Site, Wuerzburg, Germany
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 448
- Registration Number
- NCT00286117
- Locations
- 🇮🇹
Research Site, Vicenza, Italy
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2006-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00280865
- Locations
- 🇲🇽
Research Site, Delegacion Cuauhtemoc, Mexico
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00278941
- Locations
- 🇬🇧
Research Site, Reading, United Kingdom
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 215
- Registration Number
- NCT00278889
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
🇧🇪Ressearch Site, Brussels, Belgium
Faslodex in McCune-Albright Syndrome
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00278915
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00274469
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Esomeprazole in PPI Failures - IMPROVE
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00272701
- Locations
- 🇸🇪
Research site, Balsta, Sweden
🇸🇪Research Site, Vasteras, Sweden
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2007-02-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT00272740
- Locations
- 🇨🇭
Research Site, St.Gallen, Switzerland
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00272753
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
© Copyright 2024. All Rights Reserved by MedPath